Wolfe Research initiated coverage of Olema Oncology (OLMA) with a Peer Perform rating and no price target Olema is pursuing development in second-line metastatic breast cancer and first-line mBC for lead candidate palazestrant, notes the analyst, who adds that the “most important item to watch is if the drug shows convincing activity in both ESR1- mt and ESR1-wt” patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology assumed with a Buy at Jefferies
- Olema Oncology price target raised to $58 from $55 at JPMorgan
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
- Olema Oncology price target lowered to $38 from $40 at Guggenheim
- Olema Oncology price target raised to $62 from $60 at Citi